5 results about "Microbial disease" patented technology

Novel compositions are described, each comprising at least one active constituent that has a 12-carbon atom backbone as a 12-carbon chain base structure having at least a sub-terminal nitrogen and no terminal amino group. One of the active constituents is Boc-12-Ado-OH (BOA) and / or N,N-dimethyldodecylamine N-oxide (LO). Novel particle or liposomal compositions comprising at least BOA and / or LO may be prepared with an emulsifier and / or lipid and optionally a biopolymer, and may be formulated into pharmaceutically acceptable formulations and / or medicaments with or without one or more pharmaceutically acceptable carriers or excipients for utilization as an antimicrobial against one or more microbial pathogens. The novel antimicrobial compositions have broad-spectrum growth inhibitory or other destructive activity against microbial pathogens, biofilms produced by one or more pathogens, and biofilm infections.

The application discloses a microbial disease diagnosis integrated learning method for promoting diversity and keeping distribution, and mainly relates to the technical field of microorganisms, and aims to solve the defects of the resampling method, the limitations of the deep learning method in small sample and extreme imbalance scenes, and the problems of the traditional integrated learning method in diversity, computational overhead and distribution keeping. The method comprises the following steps: determining the corresponding base classifier according to the class imbalance rate of the candidate balanced subset; evaluating the classification accuracy and error rate by using the prediction probability, and constructing an effective base model pool corresponding to the balanced subset; determining the weight matrix corresponding to the base classifier by using the candidate balanced subset; pruning the effective base model pool of the base classifier by using the weight matrix to obtain a pruned base classifier; and performing weighted integration processing on the pruned base classifier by using a weighted fusion mechanism, and outputting a prediction result by using the comprehensive quality score of each model of the pruned base classifier.

This invention relates to the field of artificial intelligence technology, specifically to a method for predicting microbial diseases based on the cross-fusion of phylogenetic and abundance data. First, it collects raw metagenomic sequencing data and corresponding species abundance information to construct an initial dataset, builds a model-specific microbial lexicon, and transforms biological entities into symbolic representations that can be processed by deep learning models. Then, it vectorizes the microbial data. Next, a Cross-Attention module is used to achieve cross-modal interaction and fusion between sequence features and abundance features, providing a powerful model for disease phenotype prediction tasks, which is then trained and optimized. Finally, through transfer learning, the discriminative knowledge learned by the model in classification tasks is transformed into topological connections in the network. This allows network centrality analysis to quantify the pivotal importance of each microorganism from the "model decision-making perspective," thereby identifying key biomarkers that are both strongly correlated with disease and located at the ecological core, achieving a transformation from prediction to discovery.

The present invention belongs to the fields of infectious microbial diseases and medicines. Provided is the use of compound 5928-0054 in the preparation of a drug against Staphylococcus aureus hemolysin. It is found that compound 5928-0054 can neutralize the toxicity of Staphylococcus aureus hemolysin, exhibits a protective effect on mice infected with MRSA Staphylococcus aureus USA300, and can be used in the preparation of a drug against Staphylococcus aureus hemolysin and a drug for preventing or treating Staphylococcus aureus infections. Compound 5928-0054 is found to have a new pharmaceutical value, i.e. providing a new drug for the prevention and treatment of Staphylococcus aureus infections. Compound 5928-0054 can neutralize hemolysin, the major virulence factor of Staphylococcus aureus, thereby alleviating inflammatory injuries.